A Phase 3 interventional study of Salbutamol HFA-134a and Salbutamol HFA-152a in Asthma, sponsored by GlaxoSmithKline. Completed at 102 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies testing albuterol in Asthma — 8 open to participants now, 9 under way, 1 of them phase 3. Albuterol · Asthma.
Among the 72 studies testing albuterol in Asthma, this one is the 3rd largest by enrollment, is one of 9 that started in 2024, is one of 15 in phase 3, and was the 62nd registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →8 of the 72 studies testing albuterol in Asthma are open now, in 6 countries. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 18–75
Massachusetts General Hospital · Sites in United States
Ages 18–54
University of British Columbia · Sites in Canada
Ages 18–55 · Healthy volunteers
GlaxoSmithKline · Sites in United Kingdom
Ages 18–65
Hat Yai Medical Education Center · Sites in Thailand
Ages 18–60
By country, each count listing its studies:
Albuterol: first FDA approval 1981 (PROVENTIL). What it is approved for, and how studies give it, is on its page →
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
First in 1993; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 471 is above the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 63 across the 72 interventional studies. Of the 53 that completed or were terminated, 27 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 72 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 117 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 242 (90%) have results posted.
262 studies in Asthma by GlaxoSmithKline: 7 open now, 12 under way, 7 of them phase 3. Of 240 finished, 132 (55%) have results posted.
Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 46th largest by enrollment of the 238 interventional ones that give a count, is one of 8 that started in 2024, is one of 61 in phase 3, and was the 248th registered.
GlaxoSmithKline’s Asthma studies by the year they started, since 1999.
2 of the studies testing albuterol in Asthma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06433921GlaxoSmithKlineA Study to Compare the Relative Potency of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152a to HFA-134a in Mild Asthmatics Aged 18 to 65 Inclusive | 2027-04-16 |
| NCT07166939Massachusetts General Hospital45th Multicenter Airway Research Collaboration | 2027-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 72 studies testing albuterol in Asthma, from their registry updates:
Among GlaxoSmithKline’s 262 in Asthma:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged >=18 years with asthma
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Asthma for ≥ 6 months, defined as:
Receiving one of the following asthma treatments, at a stable dose (applicable to daily Inhaled (ICS), ICS/Long-acting bronchodilator (LABA), and ICS/LABA/Long-acting muscarinic antagonist [LAMA]), for at least 12 weeks prior to the screening visit, with treatment that is anticipated to remain stable for the duration of the study:
Asthma Control Status
Asthma that has remained stable with no severe exacerbations in the last 6 months. Severe exacerbation defined as:
Participants on as-needed SABA only, or daily maintenance ICS (plus as needed SABA):
Who do not have a documented history of reversibility within the past 2 years will need to demonstrate reversibility during the screening period.
Participants on daily maintenance ICS/LABA or ICS/LABA/LAMA:
Do not need to demonstrate reversibility in accordance with the above definition during the screening period. A reversibility maneuver will be performed to characterize the degree of post-bronchodilator change.
Participants should be able to withhold SABA for ≥6 hours and LABA-/ LAMA containing medications for ≥24 hours for the purposes of performing screening spirometry.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with asthma received inhalation of 200 microgram (ug) (2\*100 ug) or as needed up to maximum 800 µg once daily Salbutamol HFA-152a (Test) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 \& 12 and a Follow-up visit at Week 13.
Drug: Salbutamol HFA-152a
Participants with asthma received inhalation of 200 microgram (ug) (2\*100 ug) once daily plus as needed up to maximum 800 of µg Salbutamol HFA-134a (Reference) via metered dose inhaler (MDI) suspension at 30 second intervals per actuation. Participants attended 5 On-treatment visits at Weeks 0 (Day 1), 1, 4, 8 \& 12 and a Follow-up visit at Week 13.
Drug: Salbutamol HFA-134a
100 microgram (μg) (ex-valve) at 30-second intervals per actuation
100 μg (ex-valve) at 30-second intervals per actuation
Number of Participants With Adverse Events (AEs) During Run-in Period
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Adverse Events (AEs) During Treatment Period
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: From randomization (Day 1) up to Week 13 (Follow up) during treatment period
Number of Participants With Serious Adverse Events (SAEs) During Run-in Period
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: From Week -1 up to randomization (Day 1) during Run-in period
Number of Participants With Serious Adverse Events (SAEs) During Treatment Period
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
Time frame: From randomization (Day 1) up to Week 13 (Follow up) during treatment period
Absolute Values of Minimum Serum Potassium
Blood samples were collected to analyze minimum serum potassium.
Time frame: Up to Week 13 (Follow up)
Absolute Values of Serum Potassium at Each Assessed Visit
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline (CFB) in Serum Potassium at Each Assessed Visit
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Erythrocytes
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Volume (MCV)
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCV
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Mean Corpuscular Hemoglobin (MCH)
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: MCH
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Percentage of Reticulocytes
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Percentage of Reticulocytes
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and Platelets
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hemoglobin (Hgb)
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hemoglobin (Hgb)
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Hematology Parameter: Hematocrit
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Calcium, Potassium, Sodium, Urea and Glucose (Non-fasting)
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Direct Bilirubin Total Bilirubin and Creatinine
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Clinical Chemistry Parameters: Alkaline Phosphatase (ALP), Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST) and Creatine Phosphokinase (CPK)
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Potential of Hydrogen (pH)
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Potential of Hydrogen (pH)
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Value of Urinalysis Parameter: Specific Gravity
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline of Urinalysis Parameter: Specific Gravity
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Number of Participants With Worst-case Urinalysis Results Post-baseline Relative to Baseline Urinalysis Dipstick Results: Occult Blood, Protein, Urobilinogen, Bilirubin, Glucose, Ketones, Leukocyte Esterase and Nitrite
Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE \& Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL \& hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result.
Time frame: Up to Week 13 (Follow up)
Absolute Values for Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Vital Signs: Pulse Rate
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Vital Signs: Pulse Rate
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for 12 Lead Electrocardiograms (ECGs) in QT Interval Corrected by Fridericia's Formula (QTcF)
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).
Time frame: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline for 12 Lead ECGs in QTcF
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Absolute Values for Heart Rate
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).
Time frame: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Heart Rate
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, mean of the pre-dose), Weeks 1, 4, 8, 12 and 13
Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score
The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose) and Week 12
Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
Time frame: Baseline (Day 1, pre-dose) and Week 12
| Milestone | All Enrolled Participants | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|---|
| Started | 471 | 0 | 0 |
| Completed | 450 | 0 | 0 |
| Not completed | 21 | 0 | 0 |
| Withdrew: Did not meet randomization criteria | 11 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 0 | 0 |
| Withdrew: Other | 1 | 0 | 0 |
| Milestone | All Enrolled Participants | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|---|
| Started | 0 | 338 | 112 |
| Completed | 0 | 326 | 108 |
| Not completed | 0 | 12 | 4 |
| Withdrew: Adverse event | 0 | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 5 | 4 |
| Withdrew: Other | 0 | 1 | 0 |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | All Enrolled Participants |
|---|---|
| Number of Participants With Adverse Events (AEs) During Run-in Period | 0 |
An AE is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Number of Participants With Adverse Events (AEs) During Treatment Period | 108 | 36 |
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | All Enrolled Participants |
|---|---|
| Number of Participants With Serious Adverse Events (SAEs) During Run-in Period | 0 |
SAE is defined as any untoward medical occurrence that; results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy), Is a suspected transmission of any infectious agent via an authorized medicinal product, other situations judged by physician, is associated with liver injury and impaired liver function. SAEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) coding system.
| Participants | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) During Treatment Period | 6 | 3 |
Blood samples were collected to analyze minimum serum potassium.
| millimoles per liter (mmol/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Absolute Values of Minimum Serum Potassium | 3.985 ± 0.2865 | 4.025 ± 0.2993 |
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1.
| millimoles per liter (mmol/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 4.261 ± 0.3679 | 4.290 ± 0.4418 |
| Week 1 | 4.284 ± 0.3664 | 4.296 ± 0.3888 |
| Week 4 | 4.281 ± 0.4115 | 4.355 ± 0.5824 |
| Week 8 | 4.285 ± 0.3820 | 4.386 ± 0.6236 |
| Week 12 | 4.317 ± 0.4455 | 4.344 ± 0.4266 |
| Week 13 | 4.309 ± 0.4237 | 4.402 ± 0.5819 |
Blood samples were collected to analyze the serum potassium. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| millimoles per liter (mmol/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| CFB to Week 1 | 0.019 ± 0.4092 | 0.004 ± 0.4337 |
| Week 4 | 0.016 ± 0.4093 | 0.058 ± 0.5889 |
| Week 8 | 0.014 ± 0.3801 | 0.079 ± 0.6324 |
| Week 12 | 0.055 ± 0.4714 | 0.046 ± 0.4546 |
| Week 13 | 0.033 ± 0.4450 | 0.084 ± 0.6125 |
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1.
| Trillion cells per Liter (10^12 cells/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 4.67 ± 0.433 | 4.66 ± 0.473 |
| Week 1 | 4.58 ± 0.436 | 4.54 ± 0.483 |
| Week 4 | 4.62 ± 0.447 | 4.61 ± 0.588 |
| Week 8 | 4.60 ± 0.440 | 4.56 ± 0.470 |
| Week 12 | 4.65 ± 0.437 | 4.65 ± 0.421 |
| Week 13 | 4.61 ± 0.416 | 4.55 ± 0.391 |
Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Trillion cells per Liter (10^12 cells/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | -0.08 ± 0.313 | -0.11 ± 0.349 |
| Week 4 | -0.06 ± 0.354 | -0.06 ± 0.527 |
| Week 8 | -0.07 ± 0.355 | -0.09 ± 0.424 |
| Week 12 | -0.02 ± 0.324 | -0.02 ± 0.314 |
| Week 13 | -0.03 ± 0.377 | -0.10 ± 0.420 |
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1.
| Femtoliter (fL) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 91.2 ± 6.67 | 92.0 ± 6.96 |
| Week 1 | 91.7 ± 6.09 | 92.8 ± 6.67 |
| Week 4 | 91.7 ± 6.59 | 92.7 ± 6.97 |
| Week 8 | 92.2 ± 6.29 | 92.6 ± 6.81 |
| Week 12 | 92.2 ± 6.38 | 92.4 ± 6.36 |
| Week 13 | 91.6 ± 6.36 | 92.0 ± 7.19 |
Blood samples were collected to analyze the hematology parameter: MCV. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Femtoliter (fL) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | 0.3 ± 3.92 | 0.8 ± 3.47 |
| Week 4 | 0.6 ± 5.08 | 0.7 ± 4.73 |
| Week 8 | 1.0 ± 4.27 | 0.7 ± 4.40 |
| Week 12 | 0.9 ± 4.81 | 0.7 ± 3.82 |
| Week 13 | 0.8 ± 4.84 | 0.4 ± 4.29 |
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1.
| Picograms (pg) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 29.63 ± 2.454 | 29.85 ± 2.426 |
| Week 1 | 29.74 ± 2.386 | 29.89 ± 2.419 |
| Week 4 | 29.67 ± 2.403 | 29.80 ± 2.609 |
| Week 8 | 29.73 ± 2.294 | 29.83 ± 2.499 |
| Week 12 | 29.75 ± 2.341 | 29.67 ± 2.290 |
| Week 13 | 29.47 ± 2.337 | 29.71 ± 2.844 |
Blood samples were collected to analyze the hematology parameter: MCH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Picograms (pg) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | 0.04 ± 1.306 | 0.09 ± 1.181 |
| Week 4 | 0.05 ± 1.732 | -0.02 ± 1.857 |
| Week 8 | 0.07 ± 1.479 | 0.07 ± 1.724 |
| Week 12 | 0.07 ± 1.571 | -0.03 ± 1.345 |
| Week 13 | -0.02 ± 1.656 | 0.03 ± 1.718 |
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1.
| Percentage of reticulocytes in blood | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 0.0093 ± 0.01646 | 0.0087 ± 0.00358 |
| Week 1 | 0.0087 ± 0.00439 | 0.0089 ± 0.00363 |
| Week 4 | 0.0088 ± 0.00435 | 0.0094 ± 0.00419 |
| Week 8 | 0.0084 ± 0.00432 | 0.0089 ± 0.00365 |
| Week 12 | 0.0086 ± 0.00468 | 0.0085 ± 0.00422 |
| Week 13 | 0.0084 ± 0.00474 | 0.0082 ± 0.00426 |
Blood samples were collected to analyze the hematology parameter: Percentage of Reticulocytes. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Percentage of reticulocytes in blood | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | -0.0007 ± 0.01655 | 0.0002 ± 0.00347 |
| Week 4 | -0.0006 ± 0.01653 | 0.0008 ± 0.00393 |
| Week 8 | -0.0009 ± 0.01626 | 0.0003 ± 0.00335 |
| Week 12 | -0.0008 ± 0.01686 | -0.0001 ± 0.00365 |
| Week 13 | -0.0001 ± 0.00380 | 0.0001 ± 0.00431 |
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1.
| Giga cells per Liter (10^9 cells/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Basophils, Baseline (Day 1, pre-dose) | 0.05359 ± 0.028877 | 0.05152 ± 0.027971 |
| Basophils, Week 1 | 0.05230 ± 0.029134 | 0.04925 ± 0.029267 |
| Basophils, Week 4 | 0.05067 ± 0.026868 | 0.05168 ± 0.026439 |
| Basophils, Week 8 | 0.05026 ± 0.029646 | 0.04689 ± 0.030374 |
| Basophils, Week 12 | 0.05027 ± 0.027454 | 0.04786 ± 0.028822 |
| Basophils, Week 13 | 0.04734 ± 0.027433 | 0.04565 ± 0.031185 |
| Eosinophils, Baseline (Day 1, pre-dose) | 0.25976 ± 0.220918 | 0.27804 ± 0.255042 |
| Eosinophils, Week 1 | 0.26076 ± 0.217017 | 0.24736 ± 0.214797 |
| Eosinophils, Week 4 | 0.24841 ± 0.208948 | 0.27383 ± 0.241679 |
| Eosinophils, Week 8 | 0.26923 ± 0.231121 | 0.24849 ± 0.234256 |
| Eosinophils, Week 12 | 0.27193 ± 0.248452 | 0.23534 ± 0.199940 |
| Eosinophils, Week 13 | 0.26438 ± 0.236614 | 0.21806 ± 0.170850 |
| Lymphocytes, Baseline (Day 1, pre-dose) | 2.00302 ± 0.630429 | 2.03857 ± 0.589753 |
| Lymphocytes, Week 1 | 1.90672 ± 0.623507 | 1.89113 ± 0.622528 |
| Lymphocytes, Week 4 | 1.92678 ± 0.672282 | 1.92589 ± 0.589312 |
| Lymphocytes, Week 8 | 1.94068 ± 0.640358 | 1.93142 ± 0.580616 |
| Lymphocytes, Week 12 | 1.90409 ± 0.590098 | 1.92398 ± 0.530670 |
| Lymphocytes, Week 13 | 1.87193 ± 0.582794 | 1.84516 ± 0.588944 |
| Monocytes, Baseline (Day 1, pre-dose) | 0.40180 ± 0.179123 | 0.40366 ± 0.146195 |
| Monocytes, Week 1 | 0.39618 ± 0.166287 | 0.37604 ± 0.172702 |
| Monocytes, Week 4 | 0.40172 ± 0.184253 | 0.37355 ± 0.183129 |
| Monocytes, Week 8 | 0.39548 ± 0.187778 | 0.38613 ± 0.167960 |
| Monocytes, Week 12 | 0.38853 ± 0.169496 | 0.37039 ± 0.157654 |
| Monocytes, Week 13 | 0.38594 ± 0.186497 | 0.35403 ± 0.156838 |
| Neutrophils, Baseline (Day 1, pre-dose) | 4.17512 ± 1.592983 | 4.00464 ± 1.475535 |
| Neutrophils, Week 1 | 4.28183 ± 1.766811 | 4.14613 ± 1.658390 |
| Neutrophils, Week 4 | 4.40694 ± 1.832157 | 4.18075 ± 1.694496 |
| Neutrophils, Week 8 | 4.38165 ± 1.711546 | 4.06113 ± 1.574423 |
| Neutrophils, Week 12 | 4.22314 ± 1.559432 | 4.08505 ± 1.560278 |
| Neutrophils, Week 13 | 4.17911 ± 1.572408 | 4.03694 ± 1.542552 |
| Platelets, Baseline (Day 1, pre-dose) | 278.0 ± 73.44 | 273.4 ± 59.21 |
| Platelets, Week 1 | 276.3 ± 77.41 | 267.7 ± 64.89 |
| Platelets, Week 4 | 282.4 ± 87.24 | 272.3 ± 63.55 |
| Platelets, Week 8 | 282.2 ± 79.92 | 270.1 ± 56.94 |
| Platelets, Week 12 | 277.7 ± 77.00 | 271.4 ± 57.94 |
| Platelets, Week 13 | 280.4 ± 85.89 | 273.5 ± 67.99 |
Blood samples were collected to analyze the hematology parameter: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils and platelets. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Giga cells per Liter (10^9 cells/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Basophils, Week 1 | -0.00057 ± 0.033195 | -0.00198 ± 0.034266 |
| Basophils, Week 4 | -0.00235 ± 0.032068 | -0.00019 ± 0.033505 |
| Basophils, Week 8 | -0.00302 ± 0.033942 | -0.00528 ± 0.032985 |
| Basophils, Week 12 | -0.00378 ± 0.031841 | -0.00447 ± 0.028892 |
| Basophils, Week 13 | -0.00644 ± 0.033980 | -0.00645 ± 0.036669 |
| Eosinophils, Week 1 | -0.00029 ± 0.155357 | -0.02425 ± 0.170405 |
| Eosinophils, Week 4 | -0.00923 ± 0.165629 | -0.00897 ± 0.171414 |
| Eosinophils, Week 8 | 0.00672 ± 0.206049 | -0.02604 ± 0.183670 |
| Eosinophils, Week 12 | 0.01083 ± 0.211799 | -0.04379 ± 0.188082 |
| Eosinophils, Week 13 | 0.01377 ± 0.195234 | -0.05177 ± 0.176464 |
| Lymphocytes, Week 1 | -0.09338 ± 0.540509 | -0.13792 ± 0.458240 |
| Lymphocytes, Week 4 | -0.07421 ± 0.650006 | -0.11364 ± 0.480933 |
| Lymphocytes, Week 8 | -0.07617 ± 0.583260 | -0.12283 ± 0.480680 |
| Lymphocytes, Week 12 | -0.11180 ± 0.579879 | -0.09951 ± 0.491659 |
| Lymphocytes, Week 13 | -0.15016 ± 0.651971 | -0.19016 ± 0.482964 |
| Monocytes, Week 1 | -0.00704 ± 0.179329 | -0.02811 ± 0.144223 |
| Monocytes, Week 4 | 0.00029 ± 0.187726 | -0.03037 ± 0.149047 |
| Monocytes, Week 8 | -0.00971 ± 0.193656 | -0.01868 ± 0.156065 |
| Monocytes, Week 12 | -0.01660 ± 0.167036 | -0.03767 ± 0.149202 |
| Monocytes, Week 13 | -0.01555 ± 0.203099 | -0.06161 ± 0.145447 |
| Neutrophils, Week 1 | 0.15803 ± 1.770649 | 0.16972 ± 1.484200 |
| Neutrophils, Week 4 | 0.25537 ± 1.885083 | 0.13215 ± 1.388442 |
| Neutrophils, Week 8 | 0.23750 ± 1.778069 | 0.06047 ± 1.539975 |
| Neutrophils, Week 12 | 0.10452 ± 1.742205 | 0.03893 ± 1.585683 |
| Neutrophils, Week 13 | 0.03147 ± 1.889040 | -0.00452 ± 1.802729 |
| Platelets, Week 1 | -1.7 ± 54.08 | -6.8 ± 37.59 |
| Platelets, Week 4 | 3.7 ± 66.30 | -1.2 ± 47.28 |
| Platelets, Week 8 | 3.3 ± 55.61 | -3.2 ± 45.86 |
| Platelets, Week 12 | -0.1 ± 58.11 | -2.3 ± 45.24 |
| Platelets, Week 13 | -0.1 ± 62.50 | 1.3 ± 60.42 |
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1.
| gram per Liter (g/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 137.8 ± 14.09 | 138.3 ± 12.92 |
| Week 1 | 135.7 ± 14.22 | 135.4 ± 13.90 |
| Week 4 | 136.6 ± 14.18 | 136.5 ± 14.06 |
| Week 8 | 136.3 ± 13.58 | 135.8 ± 13.08 |
| Week 12 | 137.9 ± 13.37 | 137.7 ± 12.64 |
| Week 13 | 135.4 ± 13.89 | 135.2 ± 13.08 |
Blood samples were collected to analyze the hematology parameter: Hgb. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| gram per Liter (g/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | -2.2 ± 8.67 | -2.7 ± 8.35 |
| Week 4 | -1.5 ± 9.48 | -2.1 ± 8.95 |
| Week 8 | -1.6 ± 10.27 | -2.4 ± 7.37 |
| Week 12 | -0.3 ± 9.48 | -0.4 ± 7.82 |
| Week 13 | -1.0 ± 10.11 | -2.3 ± 8.67 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1.
| Percentage of red blood cells in blood | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 0.4240 ± 0.03971 | 0.4261 ± 0.03703 |
| Week 1 | 0.4182 ± 0.03944 | 0.4196 ± 0.04187 |
| Week 4 | 0.4220 ± 0.04053 | 0.4239 ± 0.04257 |
| Week 8 | 0.4229 ± 0.03940 | 0.4204 ± 0.04041 |
| Week 12 | 0.4271 ± 0.03936 | 0.4275 ± 0.03777 |
| Week 13 | 0.4207 ± 0.03930 | 0.4167 ± 0.03411 |
Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Percentage of red blood cells in blood | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | -0.0059 ± 0.02640 | -0.0058 ± 0.02880 |
| Week 4 | -0.0027 ± 0.02738 | -0.0030 ± 0.03210 |
| Week 8 | -0.0012 ± 0.03068 | -0.0050 ± 0.02623 |
| Week 12 | 0.0021 ± 0.02881 | 0.0018 ± 0.02675 |
| Week 13 | 0.0012 ± 0.02983 | -0.0068 ± 0.02796 |
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1.
| millimoles per liter (mmol/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Calcium, Baseline (Day 1, pre-dose) | 2.364 ± 0.0965 | 2.371 ± 0.0893 |
| Calcium, Week 1 | 2.340 ± 0.0900 | 2.339 ± 0.0861 |
| Calcium, Week 4 | 2.349 ± 0.1074 | 2.349 ± 0.0885 |
| Calcium, Week 8 | 2.342 ± 0.0934 | 2.343 ± 0.0918 |
| Calcium, Week 12 | 2.353 ± 0.0980 | 2.363 ± 0.0937 |
| Calcium, Week 13 | 2.347 ± 0.0939 | 2.350 ± 0.1074 |
| Potassium, Baseline (Day 1, pre-dose) | 4.261 ± 0.3679 | 4.290 ± 0.4418 |
| Potassium, Week 1 | 4.284 ± 0.3664 | 4.296 ± 0.3888 |
| Potassium, Week 4 | 4.281 ± 0.4115 | 4.355 ± 0.5824 |
| Potassium, Week 8 | 4.285 ± 0.3820 | 4.386 ± 0.6236 |
| Potassium, Week 12 | 4.317 ± 0.4455 | 4.344 ± 0.4266 |
| Potassium, Week 13 | 4.309 ± 0.4237 | 4.402 ± 0.5819 |
| Sodium, Baseline (Day 1, pre-dose) | 139.4 ± 1.99 | 139.7 ± 2.24 |
| Sodium, Week 1 | 139.4 ± 2.18 | 139.3 ± 2.24 |
| Sodium, Week 4 | 139.4 ± 2.04 | 139.6 ± 2.02 |
| Sodium, Week 8 | 139.3 ± 2.35 | 139.5 ± 2.26 |
| Sodium, Week 12 | 139.3 ± 2.10 | 139.7 ± 2.26 |
| Sodium, Week 13 | 139.1 ± 2.41 | 139.9 ± 2.17 |
| Urea, Baseline (Day 1, pre-dose) | 5.128 ± 1.4893 | 4.925 ± 1.7168 |
| Urea, Week 1 | 5.145 ± 1.5623 | 4.982 ± 1.7031 |
| Urea, Week 4 | 5.281 ± 1.8774 | 5.216 ± 2.1149 |
| Urea, Week 8 | 5.192 ± 1.6692 | 5.009 ± 1.7029 |
| Urea, Week 12 | 5.160 ± 1.5244 | 5.060 ± 1.6184 |
| Urea, Week 13 | 5.303 ± 1.7150 | 5.174 ± 1.7451 |
| Glucose (non-fasting), Baseline (Day 1, pre-dose) | 5.31 ± 0.965 | 5.23 ± 0.932 |
| Glucose (non-fasting), Week 1 | 5.38 ± 1.469 | 5.50 ± 1.647 |
| Glucose (non-fasting), Week 4 | 5.55 ± 1.847 | 5.31 ± 0.972 |
| Glucose (non-fasting), Week 8 | 5.66 ± 2.023 | 5.39 ± 1.339 |
| Glucose (non-fasting), Week 12 | 5.40 ± 1.173 | 5.33 ± 1.044 |
| Glucose (non-fasting), Week 13 | 5.37 ± 1.561 | 5.13 ± 0.636 |
Blood samples were collected to analyze the Clinical Chemistry parameters: Calcium, Potassium, Sodium, Urea and Glucose (non-fasting). Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| millimoles per Liter (mmol/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Calcium, Week 1 | -0.024 ± 0.0914 | -0.031 ± 0.0851 |
| Calcium, Week 4 | -0.016 ± 0.1029 | -0.022 ± 0.0965 |
| Calcium, Week 8 | -0.022 ± 0.1015 | -0.026 ± 0.0855 |
| Calcium, Week 12 | -0.012 ± 0.1009 | -0.006 ± 0.0933 |
| Calcium, Week 13 | -0.015 ± 0.0995 | -0.014 ± 0.1077 |
| Potassium, Week 1 | 0.019 ± 0.4092 | 0.004 ± 0.4337 |
| Potassium, Week 4 | 0.016 ± 0.4093 | 0.058 ± 0.5889 |
| Potassium, Week 8 | 0.014 ± 0.3801 | 0.079 ± 0.6324 |
| Potassium, Week 12 | 0.055 ± 0.4714 | 0.046 ± 0.4546 |
| Potassium, Week 13 | 0.033 ± 0.4450 | 0.084 ± 0.6125 |
| Sodium, Week 1 | 0.0 ± 2.08 | -0.4 ± 2.09 |
| Sodium, Week 4 | 0.0 ± 2.15 | -0.1 ± 1.94 |
| Sodium, Week 8 | -0.1 ± 2.59 | -0.2 ± 2.38 |
| Sodium, Week 12 | -0.1 ± 2.17 | 0.0 ± 2.29 |
| Sodium, Week 13 | -0.3 ± 2.66 | -0.3 ± 2.45 |
| Urea, Week 1 | -0.008 ± 1.4080 | 0.065 ± 1.2567 |
| Urea, Week 4 | 0.118 ± 1.6761 | 0.273 ± 1.6778 |
| Urea, Week 8 | 0.033 ± 1.3388 | 0.083 ± 1.6924 |
| Urea, Week 12 | 0.014 ± 1.3459 | 0.166 ± 1.4426 |
| Urea, Week 13 | 0.124 ± 1.5829 | 0.202 ± 1.5834 |
| Glucose (non-fasting), Week 1 | 0.08 ± 1.453 | 0.27 ± 1.359 |
| Glucose (non-fasting), Week 4 | 0.24 ± 1.823 | 0.09 ± 0.864 |
| Glucose (non-fasting), Week 8 | 0.35 ± 1.928 | 0.16 ± 0.945 |
| Glucose (non-fasting), Week 12 | 0.09 ± 1.245 | 0.10 ± 0.933 |
| Glucose (non-fasting), Week 13 | 0.06 ± 1.479 | 0.08 ± 0.754 |
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1.
| micromoles per Liter (umol/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Direct Bilirubin, Baseline (Day 1, pre-dose) | 2.5 ± 1.33 | 2.4 ± 1.07 |
| Direct Bilirubin, Week 1 | 2.5 ± 1.32 | 2.3 ± 1.07 |
| Direct Bilirubin, Week 4 | 2.5 ± 1.33 | 2.3 ± 1.06 |
| Direct Bilirubin, Week 8 | 2.5 ± 1.35 | 2.2 ± 1.08 |
| Direct Bilirubin, Week 12 | 2.5 ± 1.87 | 2.4 ± 1.19 |
| Direct Bilirubin, Week 13 | 2.5 ± 1.59 | 2.4 ± 1.10 |
| Total Bilirubin, Baseline (Day 1, pre-dose) | 7.3 ± 4.63 | 6.4 ± 3.59 |
| Total Bilirubin, Week 1 | 7.1 ± 4.28 | 6.0 ± 3.12 |
| Total Bilirubin, Week 4 | 7.2 ± 4.39 | 6.5 ± 3.49 |
| Total Bilirubin, Week 8 | 7.2 ± 4.65 | 6.0 ± 2.87 |
| Total Bilirubin, Week 12 | 7.5 ± 5.22 | 6.8 ± 4.41 |
| Total Bilirubin, Week 13 | 7.3 ± 5.19 | 6.7 ± 3.28 |
| Creatinine, Baseline (Day 1, pre-dose) | 74.7 ± 16.94 | 72.4 ± 16.64 |
| Creatinine, Week 1 | 74.6 ± 17.28 | 72.7 ± 16.43 |
| Creatinine, Week 4 | 75.4 ± 18.36 | 73.7 ± 16.57 |
| Creatinine, Week 8 | 74.1 ± 17.07 | 72.5 ± 14.84 |
| Creatinine, Week 12 | 74.9 ± 18.67 | 73.7 ± 18.57 |
| Creatinine, Week 13 | 76.4 ± 18.85 | 71.3 ± 14.54 |
Blood samples were collected to analyze the Clinical Chemistry parameters: Direct Bilirubin Total Bilirubin and Creatinine. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| micromoles per Liter (umol/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Direct Bilirubin, Week 1 | 0.1 ± 1.05 | -0.1 ± 1.08 |
| Direct Bilirubin, Week 4 | 0.0 ± 1.27 | -0.1 ± 1.14 |
| Direct Bilirubin, Week 8 | 0.0 ± 1.17 | -0.2 ± 1.32 |
| Direct Bilirubin, Week 12 | 0.0 ± 1.77 | 0.1 ± 1.16 |
| Direct Bilirubin, Week 13 | 0.0 ± 1.32 | -0.1 ± 1.16 |
| Total Bilirubin, Week 1 | -0.2 ± 3.79 | -0.4 ± 3.12 |
| Total Bilirubin, Week 4 | -0.1 ± 4.38 | 0.1 ± 3.76 |
| Total Bilirubin, Week 8 | -0.1 ± 4.34 | -0.4 ± 3.24 |
| Total Bilirubin, Week 12 | 0.1 ± 4.55 | 0.4 ± 3.90 |
| Total Bilirubin, Week 13 | 0.2 ± 4.31 | 0.0 ± 3.49 |
| Creatinine, Week 1 | -0.3 ± 12.87 | 0.4 ± 10.66 |
| Creatinine, Week 4 | 0.5 ± 13.67 | 1.2 ± 12.68 |
| Creatinine, Week 8 | -0.9 ± 12.00 | 0.1 ± 10.50 |
| Creatinine, Week 12 | -0.2 ± 14.25 | 1.3 ± 12.70 |
| Creatinine, Week 13 | 0.4 ± 15.94 | -1.4 ± 10.52 |
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1.
| International Units per Liter (IU/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| ALP, Baseline (Day 1, pre-dose) | 75.3 ± 22.03 | 78.2 ± 25.28 |
| ALP, Week 1 | 75.5 ± 21.80 | 77.6 ± 24.96 |
| ALP, Week 4 | 77.6 ± 24.43 | 79.6 ± 24.51 |
| ALP, Week 8 | 77.7 ± 32.88 | 77.9 ± 25.06 |
| ALP, Week 12 | 77.2 ± 22.43 | 78.9 ± 25.54 |
| ALP, Week 13 | 77.5 ± 29.06 | 77.3 ± 27.52 |
| ALT, Baseline (Day 1, pre-dose) | 19.9 ± 10.56 | 19.8 ± 9.01 |
| ALT, Week 1 | 21.1 ± 15.00 | 21.0 ± 11.16 |
| ALT, Week 4 | 21.1 ± 13.59 | 24.3 ± 25.57 |
| ALT, Week 8 | 20.1 ± 13.79 | 20.4 ± 10.74 |
| ALT, Week 12 | 21.1 ± 17.32 | 19.8 ± 8.85 |
| ALT, Week 13 | 19.4 ± 10.72 | 19.8 ± 9.27 |
| AST, Baseline (Day 1, pre-dose) | 19.9 ± 7.30 | 21.2 ± 7.40 |
| AST, Week 1 | 20.6 ± 11.98 | 21.4 ± 9.36 |
| AST, Week 4 | 20.5 ± 8.83 | 23.2 ± 13.73 |
| AST, Week 8 | 19.5 ± 6.55 | 22.4 ± 12.50 |
| AST, Week 12 | 20.7 ± 10.49 | 21.0 ± 7.23 |
| AST, Week 13 | 19.0 ± 6.28 | 20.8 ± 7.73 |
| CPK, Baseline (Day 1, pre-dose) | 130.5 ± 111.95 | 148.0 ± 116.23 |
| CPK, Week 1 | 183.2 ± 564.40 | 141.2 ± 104.62 |
| CPK, Week 4 | 151.6 ± 250.70 | 167.6 ± 176.75 |
| CPK, Week 8 | 133.8 ± 126.62 | 218.7 ± 506.04 |
| CPK, Week 12 | 136.2 ± 133.57 | 147.6 ± 165.58 |
| CPK, Week 13 | 129.3 ± 112.59 | 128.7 ± 83.21 |
Blood samples were collected to analyze the Clinical Chemistry Parameters: ALP, ALT, AST and CPK. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| International Units per Liter (IU/L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| ALP, Week 1 | 0.1 ± 11.55 | -0.7 ± 12.16 |
| ALP, Week 4 | 2.3 ± 17.06 | 1.2 ± 14.15 |
| ALP, Week 8 | 2.1 ± 28.89 | -0.6 ± 11.75 |
| ALP, Week 12 | 1.9 ± 13.82 | 0.4 ± 13.55 |
| ALP, Week 13 | 3.1 ± 24.13 | -1.2 ± 19.25 |
| ALT, Week 1 | 1.1 ± 12.71 | 1.2 ± 6.53 |
| ALT, Week 4 | 1.0 ± 11.25 | 4.3 ± 22.37 |
| ALT, Week 8 | 0.0 ± 10.86 | 0.6 ± 8.39 |
| ALT, Week 12 | 1.2 ± 15.43 | 0.1 ± 8.39 |
| ALT, Week 13 | -0.4 ± 9.51 | -0.2 ± 10.44 |
| AST, Week 1 | 0.7 ± 10.85 | 0.2 ± 5.72 |
| AST, Week 4 | 0.6 ± 7.83 | 2.0 ± 12.79 |
| AST, Week 8 | -0.5 ± 5.73 | 1.1 ± 10.74 |
| AST, Week 12 | 0.8 ± 10.57 | -0.1 ± 6.19 |
| AST, Week 13 | -0.9 ± 6.24 | -1.3 ± 7.83 |
| CPK, Week 1 | 52.0 ± 555.63 | -8.0 ± 104.14 |
| CPK, Week 4 | 20.9 ± 253.26 | 18.0 ± 186.25 |
| CPK, Week 8 | 3.1 ± 109.89 | 70.5 ± 486.88 |
| CPK, Week 12 | 5.3 ± 113.13 | -0.3 ± 168.23 |
| CPK, Week 13 | -4.2 ± 111.73 | -26.3 ± 112.91 |
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1.
| Potential of Hydrogen (pH) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 6.06 ± 0.786 | 5.95 ± 0.761 |
| Week 1 | 6.00 ± 0.735 | 5.89 ± 0.727 |
| Week 4 | 6.01 ± 0.781 | 5.95 ± 0.799 |
| Week 8 | 6.03 ± 0.735 | 6.04 ± 0.689 |
| Week 12 | 6.01 ± 0.764 | 5.97 ± 0.752 |
| Week 13 | 6.00 ± 0.773 | 6.06 ± 0.689 |
Urine samples were collected to analyze the pH. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Potential of Hydrogen (pH) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | -0.06 ± 0.832 | -0.06 ± 0.904 |
| Week 4 | -0.05 ± 0.825 | 0.00 ± 0.804 |
| Week 8 | -0.03 ± 0.805 | 0.08 ± 0.782 |
| Week 12 | -0.06 ± 0.813 | 0.00 ± 0.824 |
| Week 13 | -0.04 ± 0.842 | 0.06 ± 0.969 |
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1.
| Ratio | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 1.0173 ± 0.01646 | 1.0156 ± 0.00932 |
| Week 1 | 1.0159 ± 0.00889 | 1.0165 ± 0.01003 |
| Week 4 | 1.0160 ± 0.00861 | 1.0106 ± 0.04960 |
| Week 8 | 1.0161 ± 0.00813 | 1.0153 ± 0.00866 |
| Week 12 | 1.0160 ± 0.00811 | 1.0168 ± 0.01469 |
| Week 13 | 1.0164 ± 0.00857 | 1.0164 ± 0.01308 |
Urine samples were collected to analyze the Specific Gravity. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Ratio | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | -0.0015 ± 0.01580 | 0.0008 ± 0.01057 |
| Week 4 | -0.0015 ± 0.01665 | -0.0051 ± 0.04913 |
| Week 8 | -0.0014 ± 0.01656 | -0.0002 ± 0.00992 |
| Week 12 | -0.0015 ± 0.01648 | 0.0013 ± 0.01653 |
| Week 13 | -0.0005 ± 0.01059 | 0.0007 ± 0.01318 |
Urinalysis parameters were assessed using standard Urinalysis dipsticks and categorized according to the semi-quantitative scale provided by the test strip manufacturer (e.g.,negative, trace, 1+,2+,3+,where applicable). For each parameter, worsening from baseline was defined as a shift from a lower category (Increased to TRACE \& Non-hemolyzed TRACE), to a higher category (Increased to 1+, 2+, 3+, 4+, or 1, 2,4, 8 mg/dL \& hemolyzed TRACE), indicating a greater degree of abnormality. The worst post-baseline category observed during the study was compared with the baseline category to derive a worst-case post-baseline change classification. Participants were categorized according to the magnitude of worsening observed (e.g.,No Change/Decreased, Increase to TRACE, Increase to 1+, Increase to 2+, etc., as applicable for the parameter assessed). Values that trend towards 'normal' or a lower category (i.e. from 2+ to 1+) indicates a shift towards /return to a negative result.
| Participants | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Occult Blood, No Change/Decreased | 279 | 90 |
| Occult Blood, Increase to NON-HEMOLYZED TRACE | 15 | 6 |
| Occult Blood, Increase to NON-HEMOLYZED MODERATE | 0 | 0 |
| Occult Blood, Increase to HEMOLYZED TRACE | 3 | 1 |
| Occult Blood, Increase to 1+ | 7 | 4 |
| Occult Blood, Increase to 2+ | 14 | 4 |
| Occult Blood, Increase to 3+ | 17 | 7 |
| Protein, No Change/Decreased | 276 | 93 |
| Protein, Increase to TRACE | 38 | 11 |
| Protein, Increase to 1+ | 16 | 5 |
| Protein, Increase to 2+ | 3 | 1 |
| Protein, Increase to 3+ | 1 | 2 |
| Protein, Increase to 4+ | 1 | 0 |
| Urobilinogen, No Change/Decreased | 321 | 102 |
| Urobilinogen, Increase to 1 mg/dL | 14 | 9 |
| Urobilinogen, Increase to 2 mg/dL | 0 | 0 |
| Urobilinogen, Increase to 4 mg/dL | 0 | 1 |
| Urobilinogen, Increase to 8 mg/dL | 0 | 0 |
| Bilirubin, No Change/Decreased | 314 | 105 |
| Bilirubin, Increase to 1+ | 15 | 6 |
| Bilirubin, Increase to 2+ | 4 | 1 |
| Bilirubin, Increase to 3+ | 2 | 0 |
| Glucose, No Change/Decreased | 330 | 110 |
| Glucose, Increase to TRACE | 2 | 0 |
| Glucose, Increase to 1+ | 0 | 0 |
| Glucose, Increase to 2+ | 1 | 0 |
| Glucose, Increase to 3+ | 0 | 1 |
| Glucose, Increase to 4+ | 2 | 1 |
| Ketones, No Change/Decreased | 313 | 105 |
| Ketones, Increase to TRACE | 12 | 4 |
| Ketones, Increase to 1+ | 5 | 1 |
| Ketones, Increase to 2+ | 3 | 2 |
| Ketones, Increase to 3+ | 1 | 0 |
| Ketones, Increase to 4+ | 1 | 0 |
| Leukocyte Estererase, No Change/Decreased | 307 | 93 |
| Leukocyte Estererase, Increase to TRACE | 5 | 2 |
| Leukocyte Estererase, Increase to 1+ | 9 | 7 |
| Leukocyte Estererase, Increase to 2+ | 10 | 6 |
| Leukocyte Estererase, Increase to 3+ | 4 | 4 |
| Leukocyte Estererase, Increase to 4+ | 0 | 0 |
| Nitrite, No Change/Decreased | 331 | 111 |
| Nitrite, Increase to POSITIVE | 4 | 1 |
SDP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.
| millimeters of mercury (mm Hg) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Systolic Blood Pressure, Baseline (Day 1, pre-dose) | 122.0 ± 12.93 | 121.0 ± 11.73 |
| Systolic Blood Pressure, Week 1 | 122.8 ± 12.72 | 120.1 ± 11.49 |
| Systolic Blood Pressure, Week 4 | 121.8 ± 12.27 | 120.8 ± 10.54 |
| Systolic Blood Pressure, Week 8 | 121.8 ± 12.29 | 121.2 ± 10.89 |
| Systolic Blood Pressure, Week 12 | 121.6 ± 12.96 | 121.4 ± 12.24 |
| Systolic Blood Pressure, Week 13 | 121.0 ± 11.87 | 120.5 ± 10.77 |
| Diastolic Blood Pressure, Baseline (Day 1, pre-dose) | 74.9 ± 9.23 | 75.4 ± 8.53 |
| Diastolic Blood Pressure, Week 1 | 75.3 ± 8.48 | 74.4 ± 7.78 |
| Diastolic Blood Pressure, Week 4 | 75.0 ± 8.50 | 75.2 ± 8.03 |
| Diastolic Blood Pressure, Week 8 | 75.3 ± 8.18 | 75.1 ± 8.60 |
| Diastolic Blood Pressure, Week 12 | 75.6 ± 8.09 | 75.0 ± 7.98 |
| Diastolic Blood Pressure, Week 13 | 74.6 ± 7.72 | 75.0 ± 7.53 |
SBP and DBP measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| millimeters of mercury (mm Hg) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Systolic Blood Pressure, Week 1 | 0.9 ± 9.11 | -0.8 ± 9.95 |
| Systolic Blood Pressure, Week 4 | 0.0 ± 9.89 | -0.2 ± 10.99 |
| Systolic Blood Pressure, Week 8 | 0.0 ± 10.36 | 0.2 ± 11.80 |
| Systolic Blood Pressure, Week 12 | -0.3 ± 11.11 | 0.1 ± 11.06 |
| Systolic Blood Pressure, Week 13 | -0.8 ± 10.24 | -0.5 ± 10.32 |
| Diastolic Blood Pressure, Week 1 | 0.5 ± 7.72 | -1.0 ± 7.88 |
| Diastolic Blood Pressure, Week 4 | 0.3 ± 8.06 | -0.2 ± 7.52 |
| Diastolic Blood Pressure, Week 8 | 0.6 ± 8.77 | -0.3 ± 8.32 |
| Diastolic Blood Pressure, Week 12 | 0.9 ± 8.82 | -0.4 ± 7.77 |
| Diastolic Blood Pressure, Week 13 | 0.7 ± 9.27 | 0.3 ± 7.39 |
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1.
| beats per minute | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 71.9 ± 10.71 | 72.3 ± 10.82 |
| Week 1 | 72.5 ± 10.28 | 71.9 ± 9.94 |
| Week 4 | 71.7 ± 9.68 | 70.4 ± 10.10 |
| Week 8 | 72.8 ± 9.72 | 71.9 ± 11.58 |
| Week 12 | 72.2 ± 10.20 | 71.0 ± 10.39 |
| Week 13 | 72.3 ± 9.86 | 70.3 ± 9.46 |
Pulse rate measurements were assessed with a completely automated device after the participant has been resting for at least 5 minutes in the supine position. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| beats per minute | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | 0.5 ± 8.59 | -0.4 ± 8.82 |
| Week 4 | -0.1 ± 8.94 | -1.9 ± 9.16 |
| Week 8 | 0.9 ± 10.46 | -0.4 ± 9.04 |
| Week 12 | 0.3 ± 9.88 | -1.4 ± 9.52 |
| Week 13 | -0.7 ± 10.51 | -1.9 ± 7.95 |
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).
| milliseconds (ms) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 400.3 ± 16.70 | 402.3 ± 20.52 |
| Week 1 | 401.3 ± 17.82 | 402.2 ± 20.10 |
| Week 4 | 401.1 ± 18.57 | 404.2 ± 19.97 |
| Week 8 | 400.4 ± 18.75 | 404.5 ± 21.66 |
| Week 12 | 401.1 ± 18.04 | 404.0 ± 19.02 |
| Week 13 | 398.6 ± 17.72 | 400.1 ± 19.37 |
A standard 12-lead ECG was obtained using an ECG machine that automatically measures QTcF intervals. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for QTc interval to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| milliseconds (ms) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | 1.1 ± 13.28 | 0.0 ± 15.53 |
| Week 4 | 0.8 ± 13.61 | 2.2 ± 14.24 |
| Week 8 | 0.2 ± 14.78 | 2.4 ± 15.55 |
| Week 12 | 1.2 ± 13.48 | 1.7 ± 16.88 |
| Week 13 | -0.7 ± 13.45 | 0.5 ± 14.50 |
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose).
| beats per minute | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Baseline (Day 1, pre-dose) | 70.5 ± 11.80 | 69.5 ± 11.57 |
| Week 1 | 71.8 ± 11.97 | 69.9 ± 11.34 |
| Week 4 | 71.7 ± 12.19 | 68.4 ± 11.25 |
| Week 8 | 72.2 ± 11.44 | 69.4 ± 11.16 |
| Week 12 | 70.7 ± 11.11 | 70.1 ± 12.00 |
| Week 13 | 71.8 ± 11.32 | 68.1 ± 10.80 |
A standard 12-lead ECG was obtained using an ECG machine that automatically measures HR. The ECG was obtained after the participant has been resting for at least 5 minutes in the supine position. Pre-dose 12-lead ECG was measured in triplicate. The 3 pre-dose measures were averaged for HR to derive one Baseline value. Each individual capture of the triplicate 12-lead ECG set was separated by 1 to 5 minutes between the first and the third ECG. Baseline was defined as the mean of the triplicate 12-lead ECG measurement from the Day 1 assessment (pre-dose). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| beats per minute | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Week 1 | 1.2 ± 8.97 | 0.4 ± 8.25 |
| Week 4 | 1.0 ± 9.66 | -1.1 ± 7.78 |
| Week 8 | 1.5 ± 10.05 | 0.1 ± 7.88 |
| Week 12 | 0.0 ± 10.42 | 0.8 ± 9.42 |
| Week 13 | -0.3 ± 9.85 | -1.8 ± 7.97 |
The ACQ-6 measures 6 attributes of asthma control and are measured with a participant completed questionnaire. ACQ-6 consists of six questionnaires about the frequency and/or severity of symptoms (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath, wheeze and rescue medication use). Each question was scored from zero (no impairment/limitation) to six (total impairment/ limitation). The ACQ-6 score is calculated as the mean of the scores from the six questionnaire items. ACQ-6 score ranges from 0 to 6 with higher scores indicate greater impairment. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Scores on a scale | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Change From Baseline in Asthma Control Questionnaire-6 (ACQ-6) Score | 0.083 ± 0.5312 | 0.003 ± 0.4952 |
Forced Expiratory Volume in one second (FEV1) is defined as the volume of air forcibly exhaled in one second. Pre-bronchodilator FEV1 measurements were taken by spirometry. Baseline value was defined as the pre-dose value on Day 1. Change from Baseline was calculated as the value at indicated time point minus the value at Baseline.
| Liter (L) | Salbutamol HFA-152a MDI | Salbutamol HFA-134a MDI |
|---|---|---|
| Change From Baseline for Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1) | 0.017 ± 0.3422 | 0.056 ± 0.3257 |
Collected over All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected from Week -1 up to randomization (Day 1) during Run-in period and from randomization (Day 1) up to Week 13 (Follow up) during treatment period.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Salbutamol HFA-134a MDI (Run-in Period) | 0/471 (0%) | 0/471 (0%) | 0/471 (0%) |
| Salbutamol HFA-152a MDI (Treatment Period) | 0/338 (0%) | 6/338 (1.8%) | 38/338 (11.2%) |
| Salbutamol HFA-134a MDI (Treatment Period) | 0/112 (0%) | 3/112 (2.7%) | 14/112 (12.5%) |
| Event | Salbutamol HFA-134a MDI (Run-in Period) | Salbutamol HFA-152a MDI (Treatment Period) | Salbutamol HFA-134a MDI (Treatment Period) |
|---|---|---|---|
| Umbilical herniaGastrointestinal disorders | 0/471 | 0/338 | 1/112 |
| Viral infectionInfections and infestations | 0/471 | 0/338 | 1/112 |
| Alanine aminotransferase increasedInvestigations | 0/471 | 0/338 | 1/112 |
| Drug-induced liver injuryHepatobiliary disorders | 0/471 | 1/338 | 0/112 |
| CellulitisInfections and infestations | 0/471 | 1/338 | 0/112 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/471 | 1/338 | 0/112 |
| Shoulder fractureInjury, poisoning and procedural complications | 0/471 | 1/338 | 0/112 |
| BursitisMusculoskeletal and connective tissue disorders | 0/471 | 1/338 | 0/112 |
| MigraineNervous system disorders | 0/471 | 1/338 | 0/112 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/471 | 1/338 | 0/112 |
| Event | Salbutamol HFA-134a MDI (Run-in Period) | Salbutamol HFA-152a MDI (Treatment Period) | Salbutamol HFA-134a MDI (Treatment Period) |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 0/471 | 16/338 | 5/112 |
| NasopharyngitisInfections and infestations | 0/471 | 10/338 | 4/112 |
| Urinary tract infectionInfections and infestations | 0/471 | 7/338 | 4/112 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/471 | 12/338 | 3/112 |
Enrolled Population included all participants who passed screening and entered the study.
| Age, Continuous(YEARS) | All Enrolled Participants |
|---|---|
| Mean | 47.2 ± 14.97 |
| Sex: Female, Male(Participants) | All Enrolled Participants |
|---|---|
| Female | 304 |
| Male | 167 |
| Race/Ethnicity, Customized(Participants) | All Enrolled Participants |
|---|---|
| American Indian or Alaska Native | 5 |
| Asian | 38 |
| Black or African American | 40 |
| Native Hawaiian or Other Pacific Islander | 1 |
| White | 362 |
| Multiple | 10 |
| Not reported | 2 |
| Unknown | 13 |
Showing the first 100 of 102 sites across 13 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.
Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.
Data sharing details ↗ · www.gsk-studyregister.com
Ran from May 2024 to primary completion in Sep 2025, 15 months.
Results were first posted in Oct 2026, 1 year 1 month after primary completion.
Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 15 months is below that.
Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Albuterol